ad image

Company Info

Boehringer Ingelheim

Boehringer Ingelheim

CDMO

Overview

Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, offers contract manufacturing services to both small molecule and biopharmaceutical clients through their Boehringer Ingelheim Pharma Chemicals and Boehringer Ingelheim BioXcellence brands. Boehringer Ingelheim Pharma Chemicals offers highly flexible, efficient and quality-focused services at their state-of-the-art facilities for both APIs and finished dosage forms. BioXcellence offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain under one roof.
Boehringer Ingelheim
Contributions
23 Contributions1 / 2
Boehringer Ingelheim
Investment

Boehringer Ingelheim Invests Nearly $50 Million to Expand Plant in Puerto Rico

Boehringer Ingelheim

PR-M11-19-NI-014Nov 15, 2019
Boehringer Ingelheim
Clinical Data

New Data Reinforces Benefits of Spiolto® Respimat® in Improving Patient Outcomes

Boehringer Ingelheim

PR-M10-19-NI-001Oct 01, 2019
Boehringer Ingelheim

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Disease

Boehringer Ingelheim

PR-M09-19-NI-050Sep 23, 2019
Boehringer Ingelheim
Virtual Research

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Boehringer Ingelheim

PR-M08-19-NI-041-2259Aug 15, 2019
Boehringer Ingelheim
M&A

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Boehringer Ingelheim

PA2368Jul 17, 2019
Boehringer Ingelheim
Partnership

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership

Boehringer Ingelheim

PR-M08-18-NI-049Aug 13, 2018
Boehringer Ingelheim
Insulin

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim

PR-M06-18-NI-084Jun 26, 2018
Boehringer Ingelheim
Drug Development

Praxbind®, Specific Reversal Agent for Pradaxa®, Now Available in 3,200 Hospitals Nationwide

Boehringer Ingelheim

PR-M05-18-NI-034May 09, 2018
Boehringer Ingelheim

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Boehringer Ingelheim

PA4352Apr 30, 2018
Boehringer Ingelheim
FDA Approval

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Boehringer Ingelheim

PR-M04-18-NI-74Apr 20, 2018
Boehringer Ingelheim
Collaboration

Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford

Boehringer Ingelheim

PR-M04-18-NI-64-4396Apr 18, 2018
Boehringer Ingelheim
Animal Health

LEUKOCARE and Boehringer Ingelheim Enter into a Long-Term Agreement in the Field of Animal Health

Boehringer Ingelheim

PR-M04-18-NI-53Apr 16, 2018
Boehringer Ingelheim
Immuno-Oncology

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership

Boehringer Ingelheim

PR-M04-18-NI-030Apr 10, 2018
Boehringer Ingelheim
Clinical Trials

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine

Boehringer Ingelheim

PR-M04-18-NI-001Apr 02, 2018
Boehringer Ingelheim
Clinical Trial Data

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

Boehringer Ingelheim

PR-M03-18-NI-086Mar 23, 2018
Boehringer Ingelheim
Staffing

Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018

Boehringer Ingelheim

PR-M02-18-NI-012Feb 05, 2018
Boehringer Ingelheim
Drug Development

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban

Boehringer Ingelheim

PR-M01-18-NI-097Jan 31, 2018
Boehringer Ingelheim
Investment

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€

Boehringer Ingelheim

PR-M01-18-NI-010Jan 04, 2018
Boehringer Ingelheim
Business

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

Boehringer Ingelheim

PR-M12-17-NI-010-4983Dec 12, 2017
Boehringer Ingelheim
Oncology

Holiday Program Brings Hope Home to Lung Cancer Patients

Boehringer Ingelheim

PR-M12-17-NI-002Dec 08, 2017
1 / 2
0 Contributors1 / 0

No authors found

1 / 0